Stocks slipped on Tuesday as investors digested a sharp rebound from a strong sell-off last week.US Marketsread more
The FDIC on Tuesday voted to approve a five-agency revision of the post-crisis regulation known as the Volcker Rule.Financeread more
The launch follows a "preview" earlier this month that allowed only limited customers to apply.Technologyread more
At least three children held in detention centers at the Mexican border have died, in part, from the flu, a group of doctors say.Health and Scienceread more
The report was conducted by Senator Jon Kyl, R-AZ, and a team of lawyers who interviewed conservatives who use ans study Facebook.Technologyread more
U.S. interest rates will keep falling and follow global interest rates all the way down to zero, hedge fund manager Kyle Bass said.Marketsread more
Amazon is shaking the medical industry — and now Wall Street's digging up clues on exactly what it has planned.
Jefferies analyst Brian Tanquilut wrote on Friday that he suspects Amazon is growing its professional medical device business, while Wells Fargo pointed out Thursday that Amazon now owns the AmazonRX.com domain.
It's all part of the tea-leaf reading as investors try to understand how Amazon could disrupt a huge and historically difficult-to-break-into industry.
CNBC reported in May that each year, Amazon holds an annual meeting to discuss whether it should break into the pharmacy market, and this year, it's been more serious than ever.
Now, sources have said that is in talks to buy — a deal that would be an unprecedented mega-merger between a top drugstore chain and insurer. RBC Capital Markets analyst George Hill told CNBC that the companies "needed to defend the business from encroachment by Amazon. "
The news roiled , while .
According to Tanquilut, Amazon's business-to-business medical device web page was posted during the same period the company was granted wholesale distribution licenses in several states. The licensure was first reported by the St. Louis Post-Dispatch.
An Amazon spokesperson previously told CNBC by email that the company doesn't "comment on rumors or speculation."
While many have speculated these licenses could be used for drugs, Tanquilut said the timing could indicate Amazon is more interested in medical devices.
"[T]he out-of-state wholesaler license that AMZN filed with the state of Nevada revealed that AMZN did not select 'Controlled Substances' as a type of product that they would be handling," Tanquilut wrote in a Friday research note."While we acknowledge that there are prescription drugs that don't fall under the definition of 'controlled substances', the active decision to choose not to distribute those types of drugs leads us to believe that AMZN will not be using these licenses to distribute any prescription drugs[.]"
On the other hand, Wells Fargo analyst David Maris pointed out that AmazonRX.com redirects to the Amazon home page.
"We find it easy to envision that, if it entered pharmacy, Amazon could offer unique value to some customers, such as the easier ability to manage prescriptions and perhaps discounts, such as free generics to Prime users," Maris wrote. Overall, we think that even though Amazon has not stated a goal to be in pharmacy, history has shown it is better to consider Amazon's disruptive potential beforehand rather than afterward."
— CNBC's Christina Farr, Dan Mangan, Evelyn Cheng and Thomas Franck contributed to this report.